Kidney Disease
Medical Education
B.A.: Chemistry, St. Louis University, St. Louis, Missouri, 1979
Medical Degree: Case Western Reserve, Cleveland, Ohio, 1983
Residency: Internal Medicine, Emory University Medicine Program, Atlanta, Georgia, 1986
Fellowship: Nephrology, Washington University School of Medicine, St. Louis, Missouri, 1989
Honor and Awards
Listed in Best Doctors in America, 2003-2013 (Best Doctors, Inc.)
Disclosure of Financial Interests with IndustryWashington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.
Dr. Daniel W. Coyne reported the following earned financial interests during calendar year 2011. Move your mouse over a header for more info.
| Company | Royalties Royalties: When a faculty member invents or conceives a new or improved process or product, the company that manufactures the product will make royalty payments to the faculty member. Royalty payments usually are a small percentage of the company’s revenue related to that product. | Consulting &
Advisory Boards Consulting and Advisory Boards: Faculty may be paid to provide expertise to a company by being their consultant, or by serving on an advisory board. | Speaker Fees Speaker Fees: Companies may pay faculty to speak to professional audiences about their products. |
| Abbott | | $1,000-$10,000 | $25,001-$50,000 |
To learn more about Washington University's policies on collaborations with industry,
click here.
Editorial Responsibilities
Editorial Board Member
Journal of the American Society of Nephrology
Ad Hoc Reviewer
American Journal of Kidney Diseases
Selected or Recent Journal Articles
Brown AJ, Coyne DW. Bioavailable vitamin D in chronic kidney disease. Kidney Int. 2012 Jul.
Wang X, Belani S, Coyne DW, Fabbrini E, Reeds DN, Patterson BW, Mittendorfer B, Klein S. Very Low Density Lipoprotein Metabolism in Patients with Chronic Kidney Disease. Cardiorenal Med. 2012 Feb.
Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int. 2012 Jul.
Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int. 2011 Aug.
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner
C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa
L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B,
Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V,
Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D,
Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T,
Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C,
Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP
Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011 Jun 25.
Camins BC, Richmond AM, Dyer KL, Zimmerman HN, Coyne DW, Rothstein M, Fraser VJ. A crossover intervention trial evaluating the efficacy of a chlorhexidine-impregnated sponge in reducing catheter-related bloodstream infections among patients undergoing hemodialysis. Infect Control Hosp Epidemiol. 2010 Nov.
Ford BA, Eby CS, Scott MG, Coyne DW. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int. 2010 Oct.
Coyne DW. It's time to compare anemia management strategies in hemodialysis. Clin J Am Soc Nephrol. 2010 Apr.
Coyne DW, Auerbach M. Anemia management in chronic kidney disease: intravenous iron steps forward. Am J Hematol. 2010 May.
Young DO, Cheng SC, Delmez JA, Coyne DW. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients.Perit Dial Int. 2009 Sep-Oct.
Coyne DW, Brennan DC. Seeking safe and efficacious anemia management.. Semin Dial. 2009 Sep-Oct.
Gincherman Y, Moloney K, McKee C, Coyne DW.Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients. Hemodial Int. 2009 Aug 28.
Coyne DW. Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease.Expert Opin Pharmacother. 2009 Oct.
Fishbane S, Cohen DJ, Coyne DW, Djamali A, Singh AK, Wish JB.Posttransplant anemia: the role of sirolimus. Kidney Int. 2009 Aug.
Zheng S, Coyne DW, Joist H, Schuessler R, Godboldo-Brooks A, Ercole P,
Brennan DC.Iron deficiency anemia and iron losses after renal
transplantation. Transpl Int. 2009 Apr.